Publication seeks to introduce CTCA to wider audience

In June, the digital publication firm Patients Without Borders will be releasing a publication that introduces cancer patients, caregivers, and other interested parties in one of the more difficult-to-understand medical centers in the United States, the Cancer Treatment Centers of America (CTCA).

The publication, "FOCUS ON: Cancer Treatment Centers of America", which will be available at both the Patients Without Borders and CTCA websites as well as for all e-readers such as the Nook and Kindle, will give readers an in-depth look at this ever-growing medical center, providing patients and others with information on the hospitals themselves as well as its unique approach to cancer treatment, its staff of doctors and health professionals, credentials, travel help, and other pertinent information.

The publication should help shed light on CTCA, a private hospital group that for some seems secretive and for others is known only for its problems with US regulatory agencies.

Source: PRWeb

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap